
A recent study explored the impact of hypertension medications on renal function after coronary artery procedures in patients with and without diabetes. Among 297 hypertensive patients undergoing percutaneous coronary intervention (PCI), the study found that beta-blockers were an independent risk factor for worsening renal function (WRF) in those with diabetes while angiotensin-converting enzyme inhibitors (ACEI) had a protective effect in patients without diabetes. The research analyzing cystatin C levels revealed that 51% of diabetic patients and 58% of non-diabetic patients experienced WRF post-PCI. These findings emphasize the importance of personalized medication strategies for patients with different comorbidities undergoing coronary interventions.
Like
Save
Share